肠道B细胞以不依赖微生物群和抗原的方式促使NASH中代谢性T细胞活化,并通过IgA-FcR信号促进纤维化
该研究在小鼠和人类样本中探讨肠道B细胞在非酒精性脂肪性肝炎(NASH)、纤维化及NASH相关肝细胞癌(HCC)中的作用。活化的肠道B细胞在人和小鼠NASH中增多,可不依赖抗原特异性和肠道微生物群促使代谢性T细胞活化而诱导NASH;遗传或治疗性清除全身或胃肠道B细胞可预防或逆转NASH和肝纤维化。IgA分泌通过IgA-FcR信号轴激活CD11b+CCR2+F4/80+CD11c-FCGR1+肝脏髓系细胞,为纤维化诱导所必需。
要点
- 活化的肠道B细胞在小鼠和人类NASH样本中增多,可不依赖抗原特异性和肠道微生物群促使代谢性T细胞活化而诱导NASH。
- 遗传或治疗性清除全身或胃肠道B细胞可预防或逆转NASH和肝纤维化。
- IgA分泌通过IgA-FcR信号轴激活CD11b+CCR2+F4/80+CD11c-FCGR1+肝脏髓系细胞,是纤维化诱导所必需。
核心结论
- 肠道B细胞和IgA-FcR信号轴是治疗NASH的潜在治疗靶点。
- B细胞在NASH发病中具有双重作用:参与自身攻击性T细胞活化,并通过分泌免疫球蛋白(如IgA)激活单核细胞来源巨噬细胞而参与纤维化发展。
- B细胞缺失可预防HCC发生。
研究设计与样本
- C57BL/6J野生型、B细胞缺陷及不同免疫球蛋白缺陷或转基因小鼠分别喂食不同NASH诱导饮食或标准饲料6或12个月,评估NASH、纤维化和NASH诱导的HCC。
- 无特定病原体/无菌野生型和μMT小鼠(仅胃肠道含B细胞)喂食胆碱缺乏高脂饮食并接受抗CD20抗体治疗,评估NASH和纤维化。
- 分析单纯性脂肪变、NASH和肝硬化患者组织活检样本,将免疫球蛋白分泌与临床病理特征相关联。
- 对小鼠和人类肝脏及胃肠道组织进行流式细胞术、免疫组化和单细胞RNA测序分析以表征免疫细胞。
主要发现
- 活化的肠道B细胞在小鼠和人类NASH样本中增多,可不依赖抗原特异性和肠道微生物群促使代谢性T细胞活化而诱导NASH。
- 遗传或治疗性清除全身或胃肠道B细胞可预防或逆转NASH和肝纤维化。
- IgA分泌通过IgA-FcR信号轴激活CD11b+CCR2+F4/80+CD11c-FCGR1+肝脏髓系细胞,为纤维化诱导所必需。
- NASH患者活化肠道B细胞数量增多,IgA水平与活化FcRg+肝脏髓系细胞数量及肝纤维化程度呈正相关。
临床怎么用
- 作者认为,B细胞内在信号通路、分泌的免疫球蛋白以及B细胞与其他免疫细胞的相互作用是NASH联合治疗的潜在靶点,针对炎症和纤维化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The progression of non-alcoholic steatohepatitis (NASH) to fibrosis and hepatocellular carcinoma (HCC) is aggravated by auto-aggressive T cells. The gut-liver axis contributes to NASH, but the mechanisms involved and the consequences for NASH-induced fibrosis and liver cancer remain unknown. We investigated the role of gastrointestinal B cells in the development of NASH, fibrosis and NASH-induced HCC. METHODS: C57BL/6J wild-type (WT), B cell-deficient and different immunoglobulin-deficient or transgenic mice were fed distinct NASH-inducing diets or standard chow for 6 or 12 months, whereafter NASH, fibrosis, and NASH-induced HCC were assessed and analysed. Specific pathogen-free/germ-free WT and μMT mice (containing B cells only in the gastrointestinal tract) were fed a choline-deficient high-fat diet, and treated with an anti-CD20 antibody, whereafter NASH and fibrosis were assessed. Tissue biopsy samples from patients with simple steatosis, NASH and cirrhosis were analysed to correlate the secretion of immunoglobulins to clinicopathological features. Flow cytometry, immunohistochemistry and single-cell RNA-sequencing analysis were performed in liver and gastrointestinal tissue to characterise immune cells in mice and humans. RESULTS: Activated intestinal B cells were increased in mouse and human NASH samples and licensed metabolic T-cell activation to induce NASH independently of antigen specificity and gut microbiota. Genetic or therapeutic depletion of systemic or gastrointestinal B cells prevented or reverted NASH and liver fibrosis. IgA secretion was necessary for fibrosis induction by activating CD11b+CCR2+F4/80+CD11c-FCGR1+ hepatic myeloid cells through an IgA-FcR signalling axis. Similarly, patients with NASH had increased numbers of activated intestinal B cells; additionally, we observed a positive correlation between IgA levels and activated FcRg+ hepatic myeloid cells, as well the extent of liver fibrosis. CONCLUSIONS: Intestinal B cells and the IgA-FcR signalling axis represent potential therapeutic targets for the treatment of NASH. IMPACT AND IMPLICATIONS: There is currently no effective treatment for non-alcoholic steatohepatitis (NASH), which is associated with a substantial healthcare burden and is a growing risk factor for hepatocellular carcinoma (HCC). We have previously shown that NASH is an auto-aggressive condition aggravated, amongst others, by T cells. Therefore, we hypothesized that B cells might have a role in disease induction and progression. Our present work highlights that B cells have a dual role in NASH pathogenesis, being implicated in the activation of auto-aggressive T cells and the development of fibrosis via activation of monocyte-derived macrophages by secreted immunoglobulins (e.g., IgA). Furthermore, we show that the absence of B cells prevented HCC development. B cell-intrinsic signalling pathways, secreted immunoglobulins, and interactions of B cells with other immune cells are potential targets for combinatorial NASH therapies against inflammation and fibrosis.
引用
- Kotsiliti E, Leone V, Schuehle S, et al. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling. J Hepatol. 2023. PMID: 37224925. doi:10.1016/j.jhep.2023.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。